Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice

Journal of Theoretical Biology

Volumn 320, Issue , 2013, Pages 86-99

  Lignet, F ^a,b,c   Benzekry, S ^d   Wilson, S ^c   Billy, F ^e,f   Saut, O ^g   Tod, M ^h,i   You, B ^h,i   Adda Berkane, A ^j   Kassour, S ^j   Wei, M X ^j   Grenier, E ^a,b,c   Ribba, B ^c  

^a UNIVERSITÉ DE LYON   (France)

^b UNITÉ DE MATHÉMATIQUES PURES ET APPLIQUÉES   (France)

^c UNIVERSITÉ DE LYON   (France)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INRIA   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ UNIVERSITÉ LYON 1   (France)

^j ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

more..

Author keywords

Drug combination; Mathematical models; Vascular tumor growth

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN;

BLOOD; CANCER; CHEMOTHERAPY; DRUG; NUMERICAL MODEL; RODENT; THEORETICAL STUDY; TUMOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG EFFICACY; EXPERIMENTAL MODEL; MATHEMATICAL MODEL; MOLECULAR MODEL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THEORETICAL STUDY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; VASCULAR TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; CYTOTOXINS; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84872238076     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2012.12.013     Document Type: Article

References (46)

1. Ambrosi D., Preziosi L. On the closure of mass balance models for tumor growth. Math. Models Meth. Appl. Sci. 2002, 12(5):737.
2. Anderson A., Chaplain M. Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull. Math. Biol. 1998, 60(5):857-899.
3. Bartha K., Rieger H. Vascular network remodeling via vessel cooption, regression and growth in tumors. J. Theor. Biol. 2006, 241(4):903-918.
4. Billy F., Ribba B., Saut O., Morre-Trouilhet H., Colin T., Bresch D., Boissel J., Grenier E., Flandrois J. A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy. J. Theor. Biol. 2009, 260(4):545-562.
5. Bonate P., Howard D. Pharmacokinetics in Drug Development. Advances and Applications 2011, Springer, vol. 3.
6. Browder T., Butterfield C., Kräling B., Shi B., Marshall B., O'Reilly M., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000, 60(7):1878.
7. Byrne H., Chaplain M. Growth of nonnecrotic tumors in the presence and absence of inhibitors. Math. Biosci. 1995, 130(2):151-181.
8. Claret L., Girard P., Hoff P., Van Cutsem E., Zuideveld K., Jorga K., Fagerberg J., Bruno R. Model-based prediction of phase iii overall survival in colorectal cancer on the basis of phase ii tumor dynamics. J. Clin. Oncol. 2009, 27(25):4103-4108.
9. Czabanka M., Vinci M., Heppner F., Ullrich A., Vajkoczy P. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. Int. J. Cancer 2009, 124(6):1293-1300.
10. Dickson P., Hamner J., Sims T., Fraga C., Ng C., Rajasekeran S., Hagedorn N., McCarville M., Stewart C., Davidoff A. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res. 2007, 13(13):3942-3950.
11. d'Onofrio A., Gandolfi A. Tumor eradication by antiangiogenic therapy. analysis and extensions of the model by Hahnfeldt et al. (1999). Math. Biosci. 2004, 191(2):159-184.
12. Folkman J. Role of Angiogenesis in Tumor Growth and Metastasis 2002, Elsevier, vol. 29.
13. Gasparini G., Longo R., Fanelli M., Teicher B. Combination of antiangiogenic therapy with other anticancer therapies. results, challenges, and open questions. J. Clin. Oncol. 2005, 23(6):1295.
14. Greco W., Bravo G., Parsons J. The search for synergy. a critical review from a response surface perspective. Pharmacol. Rev. 1995, 47(2):331.
15. Greenspan H. Models for the growth of a solid tumor by diffusion. Stud. Appl. Math. 1972, 51(4):317-340.
16. Hahnfeldt P., Panigrahy D., Folkman J., Hlatky L. Tumor development under angiogenic signaling. Cancer Res. 1999, 59(19):4770.
17. Hatakeyama M., Kimura S., Naka T., Kawasaki T., Yumoto N., Ichikawa M., Kim J., Saito K., Saeki M., Shirouzu M., et al. A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signaling. Biochem. J. 2003, 373(Pt 2):451.
18. He K., Jin K., Wang H., Teng L. Anti-angiogenic therapy for colorectal cancer. on the way to getting better!. Hepato Gastroenterol. Curr. Med. Surg. Trends 2012, 59(116):1113.
19. Hendriks B., Hua F., Chabot J. Analysis of mechanistic pathway models in drug discovery. p38 pathway. Biotechnol. Prog. 2008, 24(1):96-109.
20. Hochster H., Hart L., Ramanathan R., Childs B., Hainsworth J., Cohn A., Wong L., Fehrenbacher L., Abubakr Y., Saif M., et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer. results of the tree study. J. Clin. Oncol. 2008, 26(21):3523-3529.
21. Jain R. Normalizing tumor vasculature with anti-angiogenic therapy. a new paradigm for combination therapy. Nature Med. 2001, 7(9):987-989.
22. Jain R. Normalization of tumor vasculature. an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58.
23. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D., Bohlen P., Kerbel R. Continuous low-dose therapy with vinblastine and vegf receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 2000, 105(8):R15.
24. Kohandel M., Kardar M., Milosevic M., Sivaloganathan S. Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies. Phys. Med. Biol. 2007, 52:3665-3677.
25. Lee D., Rieger H., Bartha K. Flow correlated percolation during vascular remodeling in growing tumors. Phys. Rev. Lett. 2006, 96(5):58104.
26. Lignet F., Calvez V., Grenier E., Ribba B. A structuram model of the vegf signaling pathway. emergence of robustness and redundancy properties. Math. Biosci. Eng. 2013, 10(1).
27. Ma J., Li S., Reed K., Guo P., Gallo J. Pharmacodynamic-mediated effects of the angiogenesis inhibitor su5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J. Pharmacol. Experimental Therapeutics 2003, 305(3):833-839.
28. Ma J., Waxman D. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Molecular Cancer Therapeutics 2008, 7(12):3670.
29. Magni P., Simeoni M., Poggesi I., Rocchetti M., De Nicolao G. A mathematical model to study the effects of drugs administration on tumor growth dynamics. Math. Biosci. 2006, 200(2):127-151.
30. Mantzaris N., Webb S., Othmer H. Mathematical modeling of tumor-induced angiogenesis. J. Math. Biol. 2004, 49(2):111-187.
31. O'Reilly M., Boehm T., Shing Y., Fukai N., Vasios G., Lane W., Flynn E., Birkhead J., Olsen B., Folkman J. Endostatin. an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88(2):277-285.
32. O'Reilly M., Holmgren L., Shing Y., Chen C., Rosenthal R., Moses M., Lane W., Cao Y., Sage E., Folkman J. Angiostatin. a novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell 1994, 79(2):315-328.
33. Pouysségur J., Dayan F., Mazure N. Hypoxia signaling in cancer and approaches to enforce tumor regression. Nature 2006, 441(7092):437-443.
34. Ribba B., Colin T., Schnell S. A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies. Theor. Biol. Med. Modell. 2006, 3(1):7.
35. Ribba B., Kaloshi G., Peyre M., Ricard D., Calvez V., Tod M., Cajavec-Bernard B., Idbaih A., Psimaras D., Dainese L., Pallud J., Cartalat-Carel S., Delattre J., Honnorat J., Grenier E., Ducray F. A tumor growth inhibition model for low-grade glioma treated with chemotherapy of radiotherapy. Clin. Cancer Res. 2012, 18(18):5071-5080.
36. Ribba B., Saut O., Colin T., Bresch D., Grenier E., Boissel J. A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents. J. Theor. Biol. 2006, 243(4):532-541.
37. Ribba B., Watkin E., Tod M., Girard P., Grenier E., You B., Giraudo E., Freyer G. A model of vascular tumor growth in mice combining longitudinal tumor size data with histological biomarkers. Euro. J. Cancer 2011, 47(3):479-490.
38. Ribba B., You B., Tod M., Girard P., Tranchand B., Trillet-Lenoir V., Freyer G. Chemotherapy may be delivered based on an integrated view of tumor dynamics. IET Syst. Biol. 2009, 3:180.
39. Rocchetti M., Simeoni M., Pesenti E., De Nicolao G., Poggesi I. Predicting the active doses in humans from animal studies: a novel approach in oncology. Euro. J. Cancer 2007, 43(12):1862-1868.
40. Scheithauer W., Schmiegel W. Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer. Onkologie 2009, 32(7):431.
41. Simeoni M., Magni P., Cammia C., De Nicolao G., Croci V., Pesenti E., Germani M., Poggesi I., Rocchetti M. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004, 64(3):1094.
42. Tong R., Boucher Y., Kozin S., Winkler F., Hicklin D., Jain R. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64(11):3731.
43. Wang Y., Sung C., Dartois C., Ramchandani R., Booth B., Rock E., Gobburu J. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin. Pharmacol. Therapeutics 2009, 86(2):167-174.
44. Wang Y., Zhang L., Sagotsky D. Simulating non-small cell lung cancer with a multiscale agent-based model. Theor. Biol. Med. Modell. 2007, 4:50.
45. Welter M., Bartha K., Rieger H. Emergent vascular network inhomogeneities and resulting blood flow patterns in a growing tumor. J. Theor. Biol. 2008, 250(2):257-280.
46. Zheng X., Wise S., Cristini V. Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method. Bull. Math. Biol. 2005, 67(2):211-259.